Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rift valley fever vaccines.

Literature DB >> 19837291

Rift valley fever vaccines.

Abstract

Rift Valley fever virus (RVFV), which belongs to the genus Phlebovirus, family Bunyaviridae, is a negative-stranded RNA virus carrying a tripartite RNA genome. RVFV is transmitted by mosquitoes and causes large outbreaks among ruminants and humans in Africa and the Arabian Peninsula. Human patients develop an acute febrile illness, followed by a fatal hemorrhagic fever, encephalitis or ocular diseases, whereas ruminants experience abortions during outbreak. Effective vaccination of both humans and ruminants is the best approach to control Rift Valley fever. This article summarizes the development of inactivated RVFV vaccine, live attenuated vaccine, and other new generation vaccines.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19837291 PMCID： PMC2764559 DOI： 10.1016/j.vaccine.2009.07.046

Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641

43 in total

1. The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice.

Authors: P Vialat; A Billecocq; A Kohl; M Bouloy
Journal: J Virol Date: 2000-02 Impact factor: 5.103

2. An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus.

Authors: M T Heise; A Whitmore; J Thompson; M Parsons; A A Grobbelaar; A Kemp; J T Paweska; K Madric; L J White; R Swanepoel; F J Burt
Journal: Epidemiol Infect Date: 2009-01-27 Impact factor: 2.451

3. An inactivated rift valley fever vaccine.

Authors: B J Barnard; M J Botha
Journal: J S Afr Vet Assoc Date: 1977-03 Impact factor: 1.474

Review 4. Rift valley fever.

Authors: B C Easterday
Journal: Adv Vet Sci Date: 1965

5. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting.

Authors:
Journal: Bull World Health Organ Date: 1983 Impact factor: 9.408

6. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection.

Authors: J D Kark; Y Aynor; C J Peters
Journal: Vaccine Date: 1985-06 Impact factor: 3.641

7. Rift Valley fever virus vaccine trial: study of side-effects in humans.

Authors: B Niklasson
Journal: Scand J Infect Dis Date: 1982

8. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep.

Authors: P Hunter; B J Erasmus; J H Vorster
Journal: Onderstepoort J Vet Res Date: 2002-03 Impact factor: 1.792

9. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters.

Authors: B S Niklasson; G F Meadors; C J Peters
Journal: Acta Pathol Microbiol Immunol Scand C Date: 1984-08

10. A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up.

Authors: J D Kark; Y Aynor; C J Peters
Journal: Am J Epidemiol Date: 1982-11 Impact factor: 4.897

66 in total

1. The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.

Authors: José-Carlos Fernandez; Agnès Billecocq; Jean Paul Durand; Catherine Cêtre-Sossah; Eric Cardinale; Philippe Marianneau; Michel Pépin; Noël Tordo; Michèle Bouloy
Journal: Clin Vaccine Immunol Date: 2011-11-09

2. Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors: Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal: Clin Vaccine Immunol Date: 2010-09-28

3. Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors: Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal: Vector Borne Zoonotic Dis Date: 2013-08-20 Impact factor: 2.133

Review 4. Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors: Colm Atkins; Alexander N Freiberg
Journal: Future Virol Date: 2017-10-23 Impact factor: 1.831

5. Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Authors: Nandadeva Lokugamage; Alexander N Freiberg; John C Morrill; Tetsuro Ikegami
Journal: J Virol Date: 2012-10-03 Impact factor: 5.103

6. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines.

Authors: Heike Hofmann; Xingxing Li; Xiaoai Zhang; Wei Liu; Annika Kühl; Franziska Kaup; Samantha S Soldan; Francisco González-Scarano; Friedemann Weber; Yuxian He; Stefan Pöhlmann
Journal: J Virol Date: 2013-02-06 Impact factor: 5.103

7. Curcumin inhibits Rift Valley fever virus replication in human cells.

Authors: Aarthi Narayanan; Kylene Kehn-Hall; Svetlana Senina; Lindsay Lundberg; Rachel Van Duyne; Irene Guendel; Ravi Das; Alan Baer; Laura Bethel; Michael Turell; Amy Lynn Hartman; Bhaskar Das; Charles Bailey; Fatah Kashanchi
Journal: J Biol Chem Date: 2012-07-30 Impact factor: 5.157